A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies. [PDF]
The Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, result from mutations in over a dozen genes. Although, adults are susceptible, the NCLs are frequently classified as pediatric neurodegenerative diseases due to their greater ...
Ryan D Geraets +7 more
doaj +2 more sources
A Case Report on the Challenging Diagnosis of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) [PDF]
Neuronal ceroid lipofuscinoses (NCLs), also referred as “Batten disease”, are a group of thirteen rare genetic conditions, which are part of the lysosomal storage disorders.
Andrea Nunes +7 more
doaj +3 more sources
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice [PDF]
The cellular etiology of seizures in CLN2 disease, a childhood-onset neurodegenerative lysosomal storage disorder caused by a deficiency of tripeptidyl peptidase 1 (TPP1), remains elusive.
Keigo Takahashi +13 more
doaj +4 more sources
Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model
Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease (Batten disease) is a rare pediatric disease, with symptom development leading to clinical diagnosis.
Kevin Knoernschild +8 more
doaj +2 more sources
Saccharomyces cerevisiae Ssd1p promotes CLN2 expression by binding to the 5′‐untranslated region of CLN2 mRNA [PDF]
In Saccharomyces cerevisiae , TFIID, which is composed of TATA‐binding protein (TBP) and a set of TBP‐associated factors (TAFs), mediates the transcription of most class II genes. Previous studies have shown that CLN2 expression was significantly ...
Yoshifumi, Ohyama +2 more
openaire +2 more sources
Conducting clinical trials in rare diseases is challenging. In trials that aim to use natural history control cohorts for evaluation of efficacy, lack of data on natural history of disease prolongs development of future therapies significantly. Therefore,
Miriam Nickel, Angela Schulz
doaj +1 more source
Background Utility studies enable preference-based quantification of a disease’s impact on patients’ health-related quality of life (HRQoL). It is often difficult to obtain utility values for rare, neurodegenerative conditions due to cognitive burden of ...
Paul Gissen +16 more
doaj +1 more source
Buffy Coat Score as a Biomarker of Treatment Response in Neuronal Ceroid Lipofuscinosis Type 2
The introduction of intracerebroventricular (ICV) enzyme replacement therapy (ERT) for treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease has produced dramatic improvements in disease management.
Siyamini Sivananthan +5 more
doaj +1 more source
Urine proteomics analysis of patients with neuronal ceroid lipofuscinoses
Summary: The neuronal ceroid lipofuscinoses (NCL) are a group of 13 rare neurodegenerative disorders characterized by accumulation of cellular storage bodies.
Katharina Iwan +8 more
doaj +1 more source
An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy [PDF]
Abstract Background Late infantile neuronal ceroid lipofuscinosis (CLN2 Batten disease) is a rare, progressive neurodegenerative disease of childhood. The natural history of motor and language regression is used to monitor the efficacy of CNS treatments. Less is known about CLN2 retinopathy.
Dorothy A. Thompson +4 more
openaire +3 more sources

